Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study

doi:10.1136/bmj.39541.534109.BE

BMJ, doi: 10.1136/bmj.39541.534109.BE, (Published 24 April 2008)

Research

Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study

Loretta Brabin, reader in women’s health¹, Stephen A Roberts, senior lecturer in statistics², Rebecca Stretch, research nurse¹, David Baxter, consultant in communicable diseases³, Gloria Chambers, programme manager screening failsafe⁴, Henry Kitchener, professor of gynaecological oncology¹, Rosemary McCann, consultant in communicable diseases⁵

¹ Academic Unit of Obstetrics and Gynaecology, St Mary’s Hospital, University of Manchester, Manchester M13 OJH, ² Health Methodology Research Group, University of Manchester, ³ Public Health Department, Stockport Primary Care Trust, Stockport, ⁴ Public Health Department, Bury Primary Care Trust, Bury, ⁵ Greater Manchester Health Protection Unit, Eccles

Correspondence to: L Brabin loretta.brabin{at}manchester.ac.uk

Objective To assess the feasibility and acceptability of deliveringa human papillomavirus (HPV) vaccine to adolescent girls.

Design Prospective cohort study.

Setting 36 secondary schools in two primary care trusts in GreaterManchester, United Kingdom.

Participants 2817 schoolgirls in year 8 (12 and 13 year olds).

Intervention Delivery of the bivalent vaccine at 0, 1, and 6months over one school year.

Main outcome measures Vaccine uptake for doses 1 and 2 of athree dose schedule.

Results Vaccine uptake was 70.6% (1989/2817) for the first doseand 68.5% (1930/2817) for the second dose. Uptake was significantlylower in schools with a higher proportion of ethnic minoritygirls (P<0.001 for trend) or higher proportion of girls entitledto free school meals (P=0.029 for trend). The main reason forparents’ refusal of vaccination was insufficient informationabout the vaccine and its long term safety. Maintaining thevaccine schedule was challenging as 16.3% (dose 1) and 23.6%(dose 2) of girls missed their vaccination day and had to beoffered alternative appointments. No serious adverse eventswere reported.

Conclusion Delivery of the first two doses of HPV vaccine toadolescent schoolgirls is encouraging, but the success of thevaccination programme depends on high coverage for the thirddose.

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to StumbleUpon StumbleUpon Add to Technorati Technorati What's this?

Relevant Articles

Economic evaluation of human papillomavirus vaccination in the United Kingdom: Mark Jit, Yoon Hong Choi, and W John Edmunds
BMJ 2008 337: a769. [Abstract] [Full Text] [PDF]

Human papillomavirus vaccination in the UK: Jane J Kim
BMJ 2008 337: a842. [Extract] [Full Text]

Effect of ethnic group should be clarified: Gee Yen Shin
BMJ 2008 336: 1146. [Extract] [Full Text] [PDF]

Some issues around consent remain unresolved: Elizabeth C F Brown
BMJ 2008 336: 1146. [Extract] [Full Text] [PDF]

HPV vaccination in the UK: Jo Waller and Jane Wardle
BMJ 2008 336: 1028-1029. [Extract] [Full Text] [PDF]

Challenges of implementing human papillomavirus (HPV) vaccination policy: Angela E Raffle
BMJ 2007 335: 375-377. [Extract] [Full Text] [PDF]

Comparison of social distribution of immunisation with measles, mumps, and rubella vaccine, England, 1991-2001: Elizabeth Middleton and Deborah Baker
BMJ 2003 326: 854. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

Kahn, J. A., Ding, L., Huang, B., Zimet, G. D., Rosenthal, S. L., Frazier, A. L. (2009). Mothers' Intention for Their Daughters and Themselves to Receive the Human Papillomavirus Vaccine: A National Study of Nurses. Pediatrics 123: 1439-1445 [Abstract] [Full text]
Fiander, A. (2009). Prophylactic human papillomavirus vaccination update. The Obstetrician and Gynaecologist 11: 133-135 [Abstract] [Full text]
Jit, M., Choi, Y. H., Edmunds, W J. (2008). Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769-a769 [Abstract] [Full text]
Kim, J. J (2008). Human papillomavirus vaccination in the UK. BMJ 337: a842-a842 [Full text]
(2008). HPV Vaccine: Uptake and Obstacles. JWatch Women's Health 2008: 4-4 [Full text]
Shin, G. Y. (2008). Effect of ethnic group should be clarified. BMJ 336: 1146-1146 [Full text]
Brown, E. C F (2008). Some issues around consent remain unresolved. BMJ 336: 1146-1146 [Full text]
Waller, J., Wardle, J. (2008). HPV vaccination in the UK. BMJ 336: 1028-1029 [Full text]

Rapid Responses:

Read all Rapid Responses

Urgent need for uptake data on 3 doses of HPV vaccine: Padmanabhan Badrinath
bmj.com, 26 Apr 2008 [Full text]
If liberty means anything at all, it means the right to tell people what they do not want to hear.: BM Hegde
bmj.com, 27 Apr 2008 [Full text]
An encouraging trial: Peter M English
bmj.com, 2 May 2008 [Full text]
Clarification on effect of ethnicity would be welcome: Gee Yen Shin
bmj.com, 12 May 2008 [Full text]
HPV vaccination: unresolved issues around consent: Elizabeth C.F. Brown
bmj.com, 13 May 2008 [Full text]
HPV vaccination in the United Kingdom: Early days..: Emmanuel Agogo
bmj.com, 14 May 2008 [Full text]
HPV vaccination coverage rate: a successful example of public health governance for a prevention strategy: Giuseppe Montagano, et al.
bmj.com, 12 Nov 2008 [Full text]
Uptake of the third dose of human papillomavirus vaccine by adolescent schoolgirls: the Manchester study: Loretta Brabin, et al.
bmj.com, 5 Dec 2008 [Full text]